<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03253133</url>
  </required_header>
  <id_info>
    <org_study_id>ICM-URC2015/34</org_study_id>
    <nct_id>NCT03253133</nct_id>
  </id_info>
  <brief_title>Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC</brief_title>
  <acronym>NIPOX</acronym>
  <official_title>Phase I Study Assessing Safety of Intraperitoneal Chemotherapy in Neoadjuvant Treatment of Peritoneal Carcinomatosis of Colorectal Origin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study determine the maximal tolerate dose&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study determine the maximal tolerate dose for the patient treated by intraperitoneal&#xD;
      chemotherapy in neoadjuvant treatment of peritoneal carcinomatosis of colorectal origin&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2016</start_date>
  <completion_date type="Actual">October 28, 2020</completion_date>
  <primary_completion_date type="Actual">October 28, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>To determine:&#xD;
- Maximum tolerated dose (MTD),</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>To evaluate Long term pharmacokinetic profile of associated targeted agents in tumoral tissue</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IP neoadjuvant chemotherapy protocol:&#xD;
Oxaliplatine will be administered in IP in a total solution of 2L of serum G5%. A continuous infusion pump of Oxycodone would be administered for the entire duration of the intraperitoneal chemotherapy. Perfusion time for the intraperitoneal chemotherapy is estimated but not limited to one and a half hour.&#xD;
Intravenous chemotherapy protocol:&#xD;
Associated Intravenous (systemic) chemotherapy is administered during IP chemotherapy including at least LVFU2 (5FU-Leucovorin) or FOLFIRI (5FU-Irinotecan) regimens and targeted therapy if needed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Dose levels of Oxaliplatin:&#xD;
4 dose levels of Oxaliplatin (85, 100, 130 and 160 mg/m²) are planned. 1 dose level is planned (-1 : 70 mg/m²) if DLT is reached at level 1&#xD;
Table 1: Dose levels&#xD;
Dose Level Dose (mg/m²) Number of patients DL -1 70 mg 3-6 DL 1 * 85 mg 3-6 DL 2 100 mg 3-6 DL 3 130 mg 3-6 DL 4 160 mg 3-6&#xD;
* Start level</description>
    <arm_group_label>Oxaliplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LV5FU or Folfiri</intervention_name>
    <description>Association of chemotherapy by LV5FU or Folfiri according pratician choice</description>
    <arm_group_label>Oxaliplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Oxycodone</description>
    <arm_group_label>Oxaliplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged over 18 years old&#xD;
&#xD;
          2. Histologically confirmed diagnosis of colorectal or appendix cancer&#xD;
&#xD;
          3. Peritoneal carcinomatosis of colorectal origin, presumed unresecable or non-optimally&#xD;
             resecable, assessed by imaging (CT scan (Computed Tomography Scanner) and MRI&#xD;
             (Magnetic Resonance Imaging)) or during a previous abdominal surgery&#xD;
&#xD;
          4. Peritoneal Carcinomatosis Index &gt; 17&#xD;
&#xD;
          5. Previous adjuvant chemotherapy is allowed&#xD;
&#xD;
          6. One or several lines of chemotherapy are allowed&#xD;
&#xD;
          7. Hemoglobin ≥ 10 g/dL (red blood transfusion is allowed if needed), neutrophils ≥&#xD;
             1.500/mm3, platelets ≥ 100.000/mm3 and white blood cells &gt; 3000 /mm3&#xD;
&#xD;
          8. Total bilirubin ≤ 1.5 Upper limit of normal (ULN), ALT or AST ≤ 3 ULN&#xD;
&#xD;
          9. Serum creatinine ≤ 1.5 ULN ; Serum calcium ≥ LLN and ≤ 1.2 x UNL ; Serum magnesium ≥&#xD;
             LLN and ≤ 1.2 x UNL ; Kalemia ≥ LLN&#xD;
&#xD;
         10. ECOG (Eastern Cooperative Oncology group) &lt; 1&#xD;
&#xD;
         11. Life expectancy higher than 8 weeks&#xD;
&#xD;
         12. Negative pregnancy test in women of childbearing potential&#xD;
&#xD;
         13. Use of an effective contraceptive method during the whole treatment and up to 6 months&#xD;
             after the completion of treatment&#xD;
&#xD;
         14. Patients affiliated to a French Social Security System&#xD;
&#xD;
         15. Signed informed consent (IC) obtained before any study specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serum uracile ≥ 16 ng/ml&#xD;
&#xD;
          2. Extra peritoneal metastatic disease (except ovarian metastases and retroperitoneal&#xD;
             nodes)&#xD;
&#xD;
          3. Patients with anesthetic or medical contraindications to surgery&#xD;
&#xD;
          4. Peripheral sensory neuropathy ≥ grade 2 at the time of signing the ICF&#xD;
&#xD;
          5. Patients previously treated with cytoreduction and followed by an intra-peritoneal&#xD;
             chemotherapy within the past 6 months.&#xD;
&#xD;
          6. Anticancer therapy (e.g. chemotherapy, radiotherapy, targeted therapy, concomitant&#xD;
             systemic immune therapy, or any experimental therapy) within 4 weeks before inclusion&#xD;
&#xD;
          7. History or presence of other cancer within the past 5 years (except adequately treated&#xD;
             in situ carcinoma of the cervix and non-melanoma skin cancer)&#xD;
&#xD;
          8. Pregnant or breastfeeding women&#xD;
&#xD;
          9. Known positive test for human immunodeficiency virus (HIV), hepatitis B or C virus or&#xD;
             patients with untreated serious infections&#xD;
&#xD;
         10. Participation in another clinical trial within 30 days prior to study entry&#xD;
&#xD;
         11. Legal incapacity or physical, psychological or mental status interfering with the&#xD;
             patient's ability to sign the informed consent or to terminate the study&#xD;
&#xD;
         12. ECG with a QT/QTc interval higher than 450 ms for men and higher than 470 ms for women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivia Sgarbura</last_name>
    <role>Study Chair</role>
    <affiliation>Institut régional du Cancer de Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut réginal du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2017</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

